We Give Shareholders a Voice
Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of The Medicines Company (the “Company”) (NASDAQ: MDCO) to Novartis AG (“Novartis”) (NYSE: NVS). Under the terms of the transaction, Novartis will acquire The Medicines Company for $85 per share in an all-cash transaction.
The investigation of The Medicines Company merger concerns whether the Board of The Medicines Company breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction and whether Novartis is underpaying for The Medicines Company shares, thus unlawfully harming The Medicines Company shareholders.
To receive more information, please fill out the form.